Telik Announces the Results of Genetic Signature Studies of Myelodysplastic Syndrome Patients Likely to Respond to Telintra® (Ezatiostat Hydrochloride, TLK199) at the Annual Meeting of the American Society of Hematology
Telik Announces Phase 1 Results of a Multicenter Study of Telintra® (Ezatiostat Hydrochloride, TLK199) in Combination with Revlimid® (Lenalidomide) in Patients with Myelodysplastic Syndrome
Telik Announces Publication of a Report of Complete Response of G-CSF Resistent Severe Idiopathic Chronic Neutropenia Following Treatment with Telintra®
Telik Announces Initiation of a Phase 2b Clinical Trial of Telintra® (Ezatiostat HCL) in Patients With Low to Intermediate-1 Risk Non-Deletion (5q) Myelodysplastic Syndrome
Telik Announces Publication in the Journal Cancer of a Phase 2 Randomized Multicenter Study of Two Extended Dosing Schedules of Oral Ezatiostat in Low to Intermediate-1 Risk Myelodysplastic Syndrome
Telik Announces Initiation of a Phase 2 Clinical Trial of Telintra® (Ezatiostat HCl) in Patients With Revlimid® Refractory or Resistant Deletion 5q Myelodysplastic Syndrome
Telik Announces Presentation of New Data on the Characterization of Novel Ezatiostat (TELINTRA®, TLK199) Analogs at American Association for Cancer Research Annual Meeting (Link to the Poster )
